Safety of low-dose heparin for intracranial stent-assisted angioplasty: a randomized controlled pilot study

J Endovasc Ther. 2009 Oct;16(5):642-8. doi: 10.1583/09-2752.1.

Abstract

Purpose: To access the safety of low-dose heparin in comparison to a high-dose regimen in patients undergoing intracranial stent-assisted angioplasty.

Methods: Sixty-four consecutive patients (53 men; mean age 54 years) undergoing stent-assisted angioplasty of 70 intracranial arterial stenoses were randomized to receive either low-dose (2000-U bolus+500 U/h) or high-dose (3000-U bolus+800 U/h) intravenous heparin during the procedure. The activated clotting time (ACT) was measured. The groups were compared for the following primary endpoints until hospital discharge: target lesion acute thrombosis, intracranial hemorrhage (ICH), and death.

Results: The overall angioplasty success rate was 93% (65/70 lesions). Stents were placed in 94.7% (36/38) and 90.6% (29/32) of patients in the low-dose and high-dose groups, respectively (p = 0.65). The primary endpoint occurred in 6% (2/33) of patients in the low-dose group versus 16% (5/31) of patients in the high-dose group (p = 0.25). Two patients, 1 patient in each group, experienced acute target lesion thrombosis during the procedure (p = NS); ICH occurred in 5 patients: 1 in the low-dose group and 4 in high-dose group (3.0% versus 12.9%, p = 0.19).

Conclusion: The use of a low-dose heparin regimen did not increase the incidence of target lesion thrombosis or ICH in this small pilot trial. Intraoperative low-dose heparin seems to be safe for patients undergoing intracranial stent-assisted angioplasty, but these data should be confirmed in a larger trial.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Angioplasty, Balloon* / adverse effects
  • Angioplasty, Balloon* / instrumentation
  • Angioplasty, Balloon* / mortality
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Female
  • Heparin / administration & dosage*
  • Heparin / adverse effects
  • Humans
  • Injections, Intravenous
  • Intracranial Arterial Diseases / drug therapy
  • Intracranial Arterial Diseases / mortality
  • Intracranial Arterial Diseases / therapy*
  • Intracranial Hemorrhages / chemically induced
  • Male
  • Middle Aged
  • Odds Ratio
  • Patient Discharge
  • Pilot Projects
  • Prospective Studies
  • Risk Assessment
  • Stents
  • Thrombosis / etiology
  • Thrombosis / prevention & control
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Heparin